VibroSense redovisade en nettoomsättning om 0,27 MSEK (0,55) i kvartalet, motsvarande en minskning m...
Redeye provides an in-depth review of AcouSort’s Q2 report and activities during and after the quart...
Redeye updates its estimates on Smart Eye following the Q2 2025 report.
Redeye initiates coverage of BICO, a leading player in the bioconvergence space.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
* Enedo drove the 6% Q2 adj. EBITA miss while Inission beat by 4% * 1.
* CEOTRONICS and GN's FalCom seem to perform well..
Q2-rapporten överraskade positivt med stark orderingång och förbättrad lönsamhet, även om nettoomsät...
Redeye comments on BioInvent’s Q2 report 2025. New positive results with BI-1206 in solid tumours an...
Redeye comments on the Q2 report. Top-line figures came in broadly in line with our expectations.
ExpreS2ion Biotechnologies driver en fas 1-studie med vaccinkandidaten ES2B-C001 på patienter med HE...
New Wave Groups Q2-rapport var svagare än väntat med lägre omsättning och resultat, främst tyngt av ...
Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expec...
Redeye is positive to GomSpace’s Q2 report published this morning, where the company slightly exceed...
With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively pro...
Redeye notes that Smart Eye’s Q2 reflected underlying solid performance, with Smart Eye reaching a k...
* Orders -10%, sales +3%, adj. EBITA -6% vs. ABGSCe * Enedo drove EBITA miss, Inission beat; Enedo b...
Redeye updates on Gentoo Media after weaker-than-expected Q2 results and lowered full-year 2025 guid...
Solwers' Q2 sales were largely in line with our expectations, but profitability was clearly below, s...
* Scale and presence underpin growth and margin expansion * Sharper execution on cross-segment syner...